180 related articles for article (PubMed ID: 18972573)
1. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone.
Vaddi HK; Banks SL; Chen J; Hammell DC; Crooks PA; Stinchcomb AL
J Pharm Sci; 2009 Aug; 98(8):2611-25. PubMed ID: 18972573
[TBL] [Abstract][Full Text] [Related]
2. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone.
Vaddi HK; Hamad MO; Chen J; Banks SL; Crooks PA; Stinchcomb AL
Pharm Res; 2005 May; 22(5):758-65. PubMed ID: 15906171
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.
Pillai O; Hamad MO; Crooks PA; Stinchcomb AL
Pharm Res; 2004 Jul; 21(7):1146-52. PubMed ID: 15290853
[TBL] [Abstract][Full Text] [Related]
4. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin.
Stinchcomb AL; Swaan PW; Ekabo O; Harris KK; Browe J; Hammell DC; Cooperman TA; Pearsall M
J Pharm Sci; 2002 Dec; 91(12):2571-8. PubMed ID: 12434400
[TBL] [Abstract][Full Text] [Related]
5. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs.
Valiveti S; Paudel KS; Hammell DC; Hamad MO; Chen J; Crooks PA; Stinchcomb AL
Pharm Res; 2005 Jun; 22(6):981-9. PubMed ID: 15948042
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion.
Kiptoo PK; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2006 Jun; 113(2):137-45. PubMed ID: 16750868
[TBL] [Abstract][Full Text] [Related]
7. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent.
Hammell DC; Stolarczyk EI; Klausner M; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Apr; 94(4):828-36. PubMed ID: 15736197
[TBL] [Abstract][Full Text] [Related]
8. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
9. N,N'-Dialkylaminoalkylcarbonyl (DAAC) prodrugs and aminoalkylcarbonyl (AAC) prodrugs of 4-hydroxyacetanilide and naltrexone with improved skin permeation properties.
Devarajan-Ketha H; Sloan KB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4078-82. PubMed ID: 21616664
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs.
Valiveti S; Hammell DC; Paudel KS; Hamad MO; Crooks PA; Stinchcomb AL
J Control Release; 2005 Feb; 102(2):509-20. PubMed ID: 15653167
[TBL] [Abstract][Full Text] [Related]
11. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.
Milewski M; Yerramreddy TR; Ghosh P; Crooks PA; Stinchcomb AL
J Control Release; 2010 Aug; 146(1):37-44. PubMed ID: 20678989
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy.
Liu KS; Sung KC; Al-Suwayeh SA; Ku MC; Chu CC; Wang JJ; Fang JY
Eur J Pharm Biopharm; 2011 Aug; 78(3):422-31. PubMed ID: 21315820
[TBL] [Abstract][Full Text] [Related]
14. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
[TBL] [Abstract][Full Text] [Related]
15. Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability.
Chen Y; Alberti I; Kalia YN
Eur J Pharm Biopharm; 2016 Feb; 99():103-13. PubMed ID: 26686649
[TBL] [Abstract][Full Text] [Related]
16. Enhanced skin permeation of naltrexone by pulsed electromagnetic fields in human skin in vitro.
Krishnan G; Edwards J; Chen Y; Benson HA
J Pharm Sci; 2010 Jun; 99(6):2724-31. PubMed ID: 20014281
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
18. Impact of ester promoieties on transdermal delivery of ketorolac.
Liu KS; Hsieh PW; Aljuffali IA; Lin YK; Chang SH; Wang JJ; Fang JY
J Pharm Sci; 2014 Mar; 103(3):974-86. PubMed ID: 24481782
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
20. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies.
Kim BY; Doh HJ; Le TN; Cho WJ; Yong CS; Choi HG; Kim JS; Lee CH; Kim DD
Int J Pharm; 2005 Apr; 293(1-2):193-202. PubMed ID: 15778057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
